Frédéric Collet was appointed to the board of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. He has served as the President of Novartis France since 2017, and as Chief Executive of Novartis Oncology in France since 2015. As of 2017, he also heads the Novartis Group Executive Committee, which brings together Novartis Pharmaceuticals and Oncology, Sandoz and Alcon. Frédéric currently sits on the board of the French Pharmaceutical Industry Trade Association (LEEM), is President of the LEEM Cancer Group, and he leads the European Family. From 2009 to 2015, Frédéric was President of Sandoz France. He also served as Vice President of the French Generics and Bio-similars Professional Association (GEMME). Before this, he was General Manager of the Ciba Vision division from 2005 to 2009. Prior to joining Ciba Vision, Frédéric spent 12 years in various managerial roles within the cosmetics division of the Henkel Group. Frédéric graduated from the Institut d’´Etudes Politiques in Paris and holds a Master’s degree in Economic Science from the University of Paris II.
Susanne Schaffert was appointed Chairperson and President of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. Prior to this, Susanne was the Head of Region Europe at Novartis Oncology, where she was responsible for leading Novartis’ Oncology Business Unit in the European Region, marketing key products in lung, breast and renal cancer as well as hematology and coordinating the entire Oncology operations for EU countries. Susanne is a member of the Novartis Oncology Executive Committee and R&D Portfolio management board, as well as a member of the Board of Novartis AG Germany and the GSK JV OTC Board. From 2010 to 2012, Susanne served as the Head of Investor Relations for Novartis Group, reporting to the Chief Financial Officer. Before this, she served as Novartis Global Franchise Head for Immunology and Infectious Diseases. Susanne first joined Novartis Germany in 1995, as a sales representative, and she has held a series of positions in Sales & Marketing with increasing responsibilities in both National and Global functions. Her roles have included Global Brand Director, Basel; Head of Marketing Oncology, Germany; Business Unit Head Oncology, Germany and Head of Northern & Central Europe for Novartis Oncology, managing a $1 billion business with more than 500 associates. Susanne holds a Ph.D. with honors in Organic Chemistry from University of Erlangen (Germany).
Jessica Toepfer was appointed to the board of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. She is a board member of Novartis Group France, as well as the Country CFO and Pharma CFO for Novartis France, since May 2016. With 20 years of finance and business performance experience in the pharmaceutical industry, Jessica has worked across a range of geographies and therapeutic areas with increasing responsibility. She joined Novartis in 1998, as part of Group BPA’s Finance Development Program and after a rotation in Basel, had assigntments over the next four years in Consumer Health Switzerland & Belgium and Pharma Morocco, before becoming Country CFO Norway, from 2003 to 2006. Jessica then returned to Basel as Finance Head Business Franchise CVM and in 2008 was named Head of Business Planning & Analysis Latin America based in Miami. In 2011, she returned to Europe as Country CFO in Portugal and in December 2013, was named CFO Middle East & North Africa (MENA) Cluster in Dubai managing a portfolio of 18 countries. Jessica holds a Bachelor of Science degree in Foreign Service from Georgetown University in Washington D.C., and a Master’s of Business Administration from HEC School of Management in Paris.